AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 41 min read$VRSK

Officer at Verisk (NASDAQ: VRSK) lines up another stock sale

Verisk (VRSK) officer Nicholas Daffan may sell 1,032 shares worth $192,498.96, part of a performance share award vested in 2026. He previously sold 20,048 shares for $3.9M in August 2026.

Original reporting
stocktitan.net
Published Sep 4, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 6, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VRSK
Neutral
high confidence
Mentioned
$VRSK
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VRSKNeutralLow
01

Why it matters

The filing provides transparency but is unlikely to move the stock significantly.

02

Market read

Relevant primarily to shareholders and short‑term traders monitoring insider activity.

03

What to watch

The sale stems from a vested performance award, not a discretionary sell‑off, which may lessen negative interpretation.

Relevance 4/10Novelty 3/10Timing: post filing

Background

Verisk Analytics (NASDAQ: VRSK) disclosed a Rule 144 filing for an officer's stock sale, a routine regulatory filing.

Company-level read

Ticker impact

$VRSKNeutralHigh confidence
Context

Form 144 filing shows Verisk officer Nicholas Daffan may sell 1,032 shares worth $192,498, a routine insider sale under $1M.

Expected impact

little to no immediate movement; possible slight downward pressure.

Evidence & confidence

The transaction size is modest relative to market cap and follows a recent larger sale, suggesting no material change in insider sentiment.

Market effects

Sector

None; Verisk operates in data analytics and insurance services, and the sale does not affect sector outlook.

Regional

None; the filing is company‑specific and does not influence broader regional markets.

Global

Minimal; only relevant to investors tracking Verisk.

Counterpoint

What could challenge this read

Some traders may view any insider sale as a bearish signal, but the small amount and recent larger sales dilute that view.

Key entities

  • company
    Verisk Analytics, Inc.

    Data analytics and risk assessment firm.

  • officer
    Nicholas Daffan

    Verisk officer selling shares under a performance award.

Read at source← All news

Related articles

SEP 8
$VRSKMed

VRSK Maintained by Barclays -- Price Target Lowered to $225

Barclays maintained an Overweight rating on Verisk Analytics (VRSK) but lowered its price target from $275 to $225. The company's stock is trading at $179.17, which GuruFocus estimates is 44.4% undervalued. Verisk has a GF Score of 78/100, indicating strong profitability and growth, but lower momentum. Insider activity shows significant selling, with $2.55 million in sales over the past three months.

gurufocus.com2 min
AUG 29
$VRSKMed

Is Verisk’s Q2 Beat, Buyback and AI Push Altering The Investment Case For Verisk Analytics (VRSK)?

Verisk Analytics (VRSK) reported Q2 2026 earnings and revenue above estimates, reaffirmed its 2026 outlook, and announced a $200M share repurchase. The company emphasized growth in AI and data analytics for insurance clients. Verisk projects $3.8B in revenue and $1.3B in earnings by 2029, with a 24% upside to its current price. The company's high debt levels and interest expenses remain key risks.

simplywall.st2 min
AUG 28
$VRSKMedAI 8/10

Verisk (VRSK) Down 4.7% Since Last Earnings Report: Can It Rebound?

Verisk (VRSK) shares fell 4.7% since its last earnings report. Q2 2026 earnings beat estimates at $1.98 per share, up 5.3% YoY. Revenue rose 4.3% to $806.3M. Underwriting and claims revenues increased 3.5% and 6.3% respectively. EBITDA grew 4.2% but net income declined 9.8% due to higher taxes and interest. The company maintained 2026 guidance and approved a dividend. Estimates have trended downward, with a Zacks Rank #3 (Hold).

finance.yahoo.com3 min
AUG 19
$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer

marketscreener.com2 min